Intellia Therapeutics, Inc. (NASDAQ:NTLA) has recently made headlines as one of the top genomics stocks to buy according to hedge funds. The company presented promising three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) at the EAACI Congress 2025, showcasing positive results in patients with hereditary angioedema (HAE).
The data revealed that all 10 patients who received a single dose of lonvo-z remained attack-free for a median of 23 months, with a remarkable 98% mean reduction in monthly HAE attacks. Additionally, positive safety outcomes were observed across all treatment dosages. The Phase 3 HAELO trial, which has seen a majority of U.S. enrollment, has successfully completed screening ahead of schedule. Intellia Therapeutics, Inc. plans to launch lonvo-z in 2027 following the submission of a Biologics License Application (BLA) in 2026.
Lonvo-z, also known as NTLA-2002, is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The therapy has been designated as an Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, as well as a PRIority MEdicines (PRIME) by the EMA, highlighting its potential for treating rare diseases.
Administered intravenously at doses ranging from 25 to 75 mg, lonvo-z demonstrated dose-dependent reductions in kallikrein protein levels and sustained efficacy over the long term, with no significant treatment-related adverse effects reported.
While Intellia Therapeutics, Inc. (NASDAQ:NTLA) shows promise as an investment opportunity, some AI stocks may offer greater potential for returns with lower risk. For those interested in exploring undervalued AI stocks with significant upside potential, particularly in the context of current economic trends, a free report on the best short-term AI stock is available.
In conclusion, Intellia Therapeutics, Inc. continues to make strides in the field of genomics with their innovative gene editing therapies. The positive results from the lonvo-z trial offer hope for patients with HAE and underscore the company’s commitment to advancing precision medicine.
